{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T06:43:41Z","timestamp":1769841821649,"version":"3.49.0"},"update-to":[{"DOI":"10.1016\/j.jad.2009.10.007","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2014,10,15]],"date-time":"2014-10-15T00:00:00Z","timestamp":1413331200000}}],"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,10,1]],"date-time":"2014-10-01T00:00:00Z","timestamp":1412121600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","award":["D144CC00002"],"award-info":[{"award-number":["D144CC00002"]}],"id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2014,10]]},"DOI":"10.1016\/j.jad.2014.07.007","type":"journal-article","created":{"date-parts":[[2014,8,13]],"date-time":"2014-08-13T05:05:36Z","timestamp":1407906336000},"page":"485-493","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"special_numbering":"C","title":["Corrigendum to \u201cEffectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of Acute Bipolar Depression\u201d [J. Affect. Disord. 121 (1\u20132) (2010) 106\u2013115]"],"prefix":"10.1016","volume":"168","author":[{"given":"Trisha","family":"Suppes","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Datto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Margaret","family":"Minkwitz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvid","family":"Nordenhem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chris","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Denis","family":"Darko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2014.07.007_bib1","series-title":"Diagnostic and Statistical Manual of Mental Disorders (DSM-IV), Text Revision","year":"2000"},{"key":"10.1016\/j.jad.2014.07.007_bib2","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/hup.908","article-title":"Factors associated with treatment nonadherence among US bipolar disorder patients","volume":"23","author":"Baldessarini","year":"2008","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.07.007_bib3","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1192\/bjp.154.5.672","article-title":"A rating scale for drug-induced akathisia","volume":"154","author":"Barnes","year":"1989","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib4","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1097\/00131746-200511000-00003","article-title":"Strategies for improving adherence to second-generation antipsychotics in patients with schizophrenia by increasing ease of use","volume":"11","author":"Burton","year":"2005","journal-title":"J. Psychiatr. Pract."},{"key":"10.1016\/j.jad.2014.07.007_bib5","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1176\/appi.ajp.162.7.1351","article-title":"A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression","volume":"162","author":"Calabrese","year":"2005","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib6","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1111\/j.1399-5618.2007.00500.x","article-title":"Lamotrigine in the acute treatment of bipolar depression: results of \ufb01ve double-blind, placebo-controlled clinical trials","volume":"10","author":"Calabrese","year":"2008","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2014.07.007_bib7","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.4088\/JCP.v65n1109","article-title":"Impact of depressive symptoms compared with manic symptoms in bipolar disorder: results of a U.S. community-based sample","volume":"65","author":"Calabrese","year":"2004","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib8","unstructured":"Cutler, A., Datto, C., Nordenhem, A., Minkwitz, M., Dettore, B., Acevedo, L., Darko, D., 2008. Effectiveness of an extended release formulation of quetiapine as monotherapy for the treatment of acute bipolar mania. In: Poster presented at the 161st Annual Meeting of the American Psychiatric Association. Washington, DC, USA, May 3\u20138."},{"key":"10.1016\/j.jad.2014.07.007_bib9","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1046\/j.1525-1497.1998.00053.x","article-title":"The interaction of patient perception of overmedication with drug compliance and side effects","volume":"13","author":"Fincke","year":"1998","journal-title":"J. Gen. Intern. Med."},{"key":"10.1016\/j.jad.2014.07.007_bib10","unstructured":"Goldstein, J.M., Christoph, G., Grimm, S., Liu, J.W., Widzowski, D., Brecher, M., 2007. Unique mechanism for the antidepressant properties of the atypical antipsychotic quetiapine. In: Presented at the 20th European College of Neuropsychopharmacology. Vienna, Austria, October."},{"key":"10.1016\/j.jad.2014.07.007_bib11","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib12","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1001\/archpsyc.62.12.1322","article-title":"Psychosocial disability in the course of bipolar I and II disorders: a prospective, comparative, longitudinal study","volume":"62","author":"Judd","year":"2005","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib13","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1001\/archpsyc.60.3.261","article-title":"A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder","volume":"60","author":"Judd","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib14","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1001\/archpsyc.59.6.530","article-title":"The long-term natural history of the weekly symptomatic status of bipolar I disorder","volume":"59","author":"Judd","year":"2002","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib15","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1176\/ajp.2006.163.9.1561","article-title":"Prevalence and effects of mood disorders on work performance in a nationally representative sample of U.S. workers","volume":"163","author":"Kessler","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib16","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1399-5618.2007.00467.x","article-title":"Three times more days depressed than manic or hypomanic in both bipolar I and bipolar II disorder","volume":"9","author":"Kupka","year":"2007","journal-title":"Bipolar Disord."},{"key":"10.1016\/j.jad.2014.07.007_bib17","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1176\/appi.ajp.163.2.232","article-title":"Risk of switch in mood polarity to hypomania or mania in patients with bipolar depression during acute and continuation trials of venlafaxine, sertraline, and bupropion as adjuncts to mood stabilizers","volume":"163","author":"Leverich","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib18","doi-asserted-by":"crossref","unstructured":"McElroy, S., Olausson, B., Chang, W., Nordenhem, A., Paulsson, B., Brecher, M., Young, A.H., 2008. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN II) [Poster]. In: Presented at the 3rd Biennial International Society for Bipolar Disorders (ISBD) Meeting. Delhi, India [Poster # 106].","DOI":"10.1016\/j.eurpsy.2008.01.451"},{"key":"10.1016\/j.jad.2014.07.007_bib19","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1001\/archpsyc.64.5.543","article-title":"Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication","volume":"64","author":"Merikangas","year":"2007","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib20","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib21","doi-asserted-by":"crossref","first-page":"680","DOI":"10.4088\/JCP.v64n0610","article-title":"Morbidity in 258 bipolar outpatients followed for 1 year with daily prospective ratings on the NIMH life chart method","volume":"64","author":"Post","year":"2003","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib22","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pharmthera.2006.07.002","article-title":"Differentiating antidepressants of the future: ef\ufb01cacy and safety","volume":"113","author":"Rosenzweig-Lipson","year":"2007","journal-title":"Pharmacol. Ther."},{"issue":"Suppl. 44","key":"10.1016\/j.jad.2014.07.007_bib23","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2014.07.007_bib24","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/S0165-1781(97)00123-6","article-title":"Modi\ufb01cation of the Clinical Global Impressions (CGI) scale for use in bipolar illness (BP): the CGI\u2013BP","volume":"73","author":"Spearing","year":"1997","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2014.07.007_bib25","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1176\/appi.ajp.2008.08020189","article-title":"Maintenance treatment for patients with bipolar I disorder: results from a North American study of quetiapine in combination with lithium or divalproex (Trial 127)","volume":"166","author":"Suppes","year":"2009","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1097\/jcp.0b013e3181618eb4","article-title":"Aripiprazole monotherapy in nonpsychotic bipolar I depression: results of 2 randomized placebo-controlled studies","volume":"28","author":"Thase","year":"2008","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.07.007_bib27","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1097\/01.jcp.0000248603.76231.b7","article-title":"Ef\ufb01cacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)","volume":"26","author":"Thase","year":"2006","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2014.07.007_bib28","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.60.11.1079","article-title":"Ef\ufb01cacy of olanzapine and olanzapine\u2013\ufb02uoxetine combination in the treatment of bipolar I depression","volume":"60","author":"Tohen","year":"2003","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2014.07.007_bib29","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1056\/NEJMsa065779","article-title":"Selective publication of antidepressant trials and its in\ufb02uence on apparent ef\ufb01cacy","volume":"358","author":"Turner","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2014.07.007_bib30","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.jad.2008.06.001","article-title":"Ef\ufb01cacy and safety of quetiapine in combination with lithium or divalproex for maintenance of patients with bipolar I disorder (international trial 126)","volume":"109","author":"Vieta","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2014.07.007_bib31","doi-asserted-by":"crossref","unstructured":"Young, A.H., McElroy, S., Chang, W., Olausson, B., Paulsson, B., Brecher, M., 2008. A double-blind, placebo-controlled study with acute and continuation phase of quetiapine in adults with bipolar depression (EMBOLDEN I) [Poster]. In: Presented at the 3rd Biennial International Society for Bipolar Disorders (ISBD) Meeting. Delhi, India [Poster # 79].","DOI":"10.1016\/j.eurpsy.2008.01.451"},{"key":"10.1016\/j.jad.2014.07.007_bib32","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1192\/bjp.133.5.429","article-title":"A rating scale for mania: reliability, validity and sensitivity","volume":"133","author":"Young","year":"1978","journal-title":"Br. J. Psychiatry"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032714004388?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032714004388?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T01:14:51Z","timestamp":1759022091000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032714004388"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,10]]},"references-count":32,"alternative-id":["S0165032714004388"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2014.07.007","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2014,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Corrigendum to \u201cEffectiveness of the Extended Release Formulation of Quetiapine as Monotherapy for the Treatment of Acute Bipolar Depression\u201d [J. Affect. Disord. 121 (1\u20132) (2010) 106\u2013115]","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2014.07.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2009.10.007","name":"associatedlink","label":"CrossRef DOI link to the associated document"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}